Trial Profile
Plerixafor (Plerixafor AMD 3100) + Recombinant Human G-CSF (rhG-CSF) for Autologous Peripheral Blood Stem Cell Transplantation (AutoSCT) in Hard to Mobilise Patients: a Phase IIB Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary) ; Granulocyte colony-stimulating factors
- Indications Stem cell mobilisation
- Focus Therapeutic Use
- 01 Jan 2016 Results published in the Acta Haematologica
- 23 Nov 2015 New trial record